JAK-STAT pathway inhibitors in dermatology
An. bras. dermatol
;
98(5): 656-677, 2023. tab, graf
Article
Dans Anglais
|
LILACS-Express
| LILACS
| ID: biblio-1505662
ABSTRACT
Abstract The JAK-STAT signaling pathway mediates important cellular processes such as immune response, carcinogenesis, cell differentiation, division and death. Therefore, drugs that interfere with different JAK-STAT signaling patterns have potential indications for various medical conditions. The main dermatological targets of JAK-STAT pathway inhibitors are inflammatory or autoimmune diseases such as psoriasis, vitiligo, atopic dermatitis and alopecia areata; however, several dermatoses are under investigation to expand this list of indications. As JAK-STAT pathway inhibitors should gradually occupy a relevant space in dermatological prescriptions, this review presents the main available drugs, their immunological effects, and their pharmacological characteristics, related to clinical efficacy and safety, aiming to validate the best dermatological practice.
Texte intégral:
Disponible
Indice:
LILAS (Amériques)
langue:
Anglais
Texte intégral:
An. bras. dermatol
Thème du journal:
Dermatologie
Année:
2023
Type:
Article
Pays d'affiliation:
Brésil
Institution/Pays d'affiliation:
Faculdade de Medicina do ABC/BR
/
Hospital de Dermatologia Sanitária do Paraná/BR
/
Universidade Estadual Paulista/BR
/
Universidade Federal de Goiás/BR
/
Universidade do Estado do Amazonas/BR
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS